Literature DB >> 29913451

Progression of Chronic Kidney Disease Affects HDL Impact on Lipoprotein Lipase (LPL)-Mediated VLDL Lipolysis Efficiency.

Agnieska Ćwiklińska1, Monika Cackowska2, Ewa Wieczorek1, Ewa Król2, Robert Kowalski3, Agnieszka Kuchta1, Barbara Kortas-Stempak1, Anna Gliwińska1, Kamil Dąbkowski1, Justyna Zielińska1, Alicja Dębska-Ślizień2, Maciej Jankowski1.   

Abstract

BACKGROUND/AIMS: Hypertriglyceridaemia (HTG) and reduction and dysfunction of high density lipoprotein (HDL) are common lipid disturbances in chronic kidney disease (CKD). HTG in CKD is caused mainly by the decreased efficiency of lipoprotein lipase (LPL)-mediated very low density lipoprotein triglyceride (VLDL-TG) lipolysis. It has not been clarified whether HDL dysfunction in CKD contributes directly to HTG development; thus, the aim of this study was to assess the impact of CKD progression on the ability of HDL to enhance LPL-mediated VLDL-TG lipolysis efficiency.
METHODS: VLDL was isolated from non-dialysis patients in CKD stages 3 and 4 and from non-CKD patients. The VLDL was incubated with LPL at the constant LPL:VLDL-TG ratio, in the absence or presence of HDL. After incubation, the VLDL was separated and the percentage (%) of hydrolyzed TG was calculated.
RESULTS: HDL presence increased the lipolysis efficiency of VLDL isolated from CKD and non-CKD patients, for the VLDL-TG> 50 mg/dl. Its effect was dependent on the VLDL-TG and HDL-cholesterol concentrations in the reaction mixtures: the higher the concentrations of VLDL-TG and HDL-cholesterol, the greater the effect. The positive impact of HDL on VLDL lipolysis was modified by CKD progression: the percentage of lipolyzed VLDL-TG in the presence of HDL decreased with a reduction in eGFR (r=0.43, p=0.009), and for patients with stage 4 CKD, no positive impact of HDL on lipolysis was observed. The percentage of lipolyzed TG correlated negatively with apoE and apoCs content in VLDL, and positively with HDL-apoCII, as well as with VLDL and HDL apoCII/ apoCIII ratios. The progression of CKD was associated with unfavourable changes in VLDL and HDL composition; apoE and apoCs levels increased in VLDL with a decrease in eGFR whereas the HDL-cholesterol level decreased.
CONCLUSION: The progression of CKD affects lipoprotein composition and properties, and modulates the positive impact of HDL on VLDL lipolysis efficiency. In CKD patients, HDL deficiency and dysfunction can directly affect hypertriglyceridaemia development.
© 2018 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Chronic kidney disease; High density lipoprotein; Lipolysis; Lipoprotein lipase; Lipoproteins; Triglycerides; Very low density lipoprotein

Mesh:

Substances:

Year:  2018        PMID: 29913451     DOI: 10.1159/000490686

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  14 in total

Review 1.  The effect of chronic kidney disease on lipid metabolism.

Authors:  Neris Dincer; Tuncay Dagel; Baris Afsar; Adrian Covic; Alberto Ortiz; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2018-12-05       Impact factor: 2.370

2.  Changes in the size and electrophoretic mobility of HDL subpopulation particles in chronic kidney disease.

Authors:  Anna Gliwińska; Agnieszka Ćwiklińska; Monika Czaplińska; Ewa Wieczorek-Breitzke; Barbara Kortas-Stempak; Agnieszka Kuchta; Alicja Dębska-Ślizień; Ewa Król; Maciej Jankowski
Journal:  J Nephrol       Date:  2022-08-09       Impact factor: 4.393

3.  Apolipoprotein E gene polymorphism and renal function are associated with apolipoprotein E concentration in patients with chronic kidney disease.

Authors:  Monika Czaplińska; Agnieszka Ćwiklińska; Monika Sakowicz-Burkiewicz; Ewa Wieczorek; Agnieszka Kuchta; Robert Kowalski; Barbara Kortas-Stempak; Alicja Dębska-Ślizień; Maciej Jankowski; Ewa Król
Journal:  Lipids Health Dis       Date:  2019-03-09       Impact factor: 3.876

4.  Predicting Factors for Rapid Progressive Chronic Kidney Disease in Primary Glomerular Disease Patients with Moderate-to-Severe Stage.

Authors:  Jun Tan; Hao Zhang; Wei Zheng; Shikun Yang; Minghui Yang; Yan Liu
Journal:  Biomed Res Int       Date:  2020-11-28       Impact factor: 3.411

5.  Decreased Efficiency of Very-Low-Density Lipoprotein Lipolysis Is Linked to Both Hypertriglyceridemia and Hypercholesterolemia, but It Can Be Counteracted by High-Density Lipoprotein.

Authors:  Ewa Wieczorek; Agnieszka Ćwiklińska; Agnieszka Kuchta; Barbara Kortas-Stempak; Anna Gliwińska; Maciej Jankowski
Journal:  Nutrients       Date:  2021-04-08       Impact factor: 5.717

Review 6.  Subpopulations of High-Density Lipoprotein: Friends or Foes in Cardiovascular Disease Risk in Chronic Kidney Disease?

Authors:  Susana Coimbra; Flávio Reis; Maria João Valente; Susana Rocha; Cristina Catarino; Petronila Rocha-Pereira; Maria Sameiro-Faria; Elsa Bronze-da-Rocha; Luís Belo; Alice Santos-Silva
Journal:  Biomedicines       Date:  2021-05-16

Review 7.  The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease.

Authors:  Jacek Rysz; Anna Gluba-Brzózka; Magdalena Rysz-Górzyńska; Beata Franczyk
Journal:  Int J Mol Sci       Date:  2020-01-17       Impact factor: 5.923

8.  Atorvastatin Improves Hepatic Lipid Metabolism and Protects Renal Damage in Adenine-Induced Chronic Kidney Disease in Sprague-Dawley Rats.

Authors:  Hardik Ghelani; Valentina Razmovski-Naumovski; Vamsi Inampudi; Dennis Chang; Srinivas Nammi
Journal:  Biomed Res Int       Date:  2019-11-05       Impact factor: 3.411

Review 9.  High-Density Lipoproteins and the Kidney.

Authors:  Arianna Strazzella; Alice Ossoli; Laura Calabresi
Journal:  Cells       Date:  2021-03-31       Impact factor: 6.600

10.  The Differential Effects of HDL Subpopulations on Lipoprotein Lipase (LPL)-Mediated VLDL Catabolism.

Authors:  Ewa Wieczorek; Agnieszka Ćwiklińska; Agnieszka Kuchta; Barbara Kortas-Stempak; Anna Gliwińska; Maciej Jankowski
Journal:  Biomedicines       Date:  2021-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.